Abstract
Introduction Pediculosis is one of the vector-borne diseases that has spread in most regions of the world and has affected many populations. In previous decades, organochlorine poisons were used to treat it. But resistance to treatment against this group of insecticides affected its control. Based on this, the present study was conducted to investigate the prevalence of Knockdown Resistance in human head lice against organochlorine insecticides in the world in the form of a systematic review and meta-analysis.
Methods To determine the prevalence of Knockdown Resistance against organochlorine insecticides, all English and non-English articles (at least with English titles and abstracts) were published worldwide without a time limit until the end of May 2022 and were extracted and analyzed. Statistical analysis of the data was done using statistical tests of fixed and random effects model in the meta-analysis, Cochrane, meta-regression, and I2 index.
Results 8 articles with a sample size of 7249 head lice were included in the meta-analysis process. The prevalence of knockdown resistance was estimated at 65.3%. Also, the prevalence of homozygote resistance was 71.9% and heterozygote resistance was 28.1%.
Conclusion Based on the findings, more than half of the lice were resistant to organochlorine insecticides. As a result, due to the high prevalence of resistance, it is recommended to determine the resistance against them before using this group of insecticides to treat pediculosis and then adopting the appropriate treatment.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors have not received any funding from any organization.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
It is not applicable.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Not Applicable
Footnotes
Email: z.nasiri1362{at}gmail.com, Mobile: +989179840495
Email: Jalal_20169{at}yahoo.com, Mobile: +989173145416
Email: zy20172017{at}yahoo.com, Mobile: +989373936440
Email: Mohseni57faryab{at}gmail.com, Mobile: +989108588424
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.